Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01958775|
Recruitment Status : Completed
First Posted : October 9, 2013
Last Update Posted : March 10, 2015
- To assess whether Glucagon like peptide 2 (GLP-2) affects lipoprotein production (study A)
- To assess whether GLP-2 affects the release of preformed chylomicrons (study B)
|Condition or disease||Intervention/treatment||Phase|
|Dyslipidemia||Drug: GLP-2 Drug: Placebo||Phase 3|
Study A: Using constant feeding with a nasoduodenal tube and stable isotope infusion, mathematical modelling will be utilised to measure lipoprotein production and clearance. The lipoproteins assessed will be apoB-100 from the liver and apoB-48 from the intestine.
StudyB: Volunteers will be given a liquid meal with retinyl palmitate (vitamin A) to label chylomicrons made from the meal. 7 hours later they will be given GLP-2 or placebo. Measurements of plasma and TRL(triglyceride rich lipoprotein) triglyceride and TRL retinyl palmitate will be carried out to see whether GLP-2 increases these parameters.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Crossover Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||June 2014|
active treatment with a single dose of GLP-2 (1500mcg)
single subcutaneous dose of 1500mcg
Other Name: glucagon like peptide 2
Placebo Comparator: Placebo
- Lipoprotein production and clearance rate [ Time Frame: 10 hours ]ApoB 100 and ApoB 48 production and clearance
- Plasma and TRL triglyceride and TRL retinyl palmitate [ Time Frame: 10 hours ]Measurements will be carried out hourly after ingestion of meal and then every 15-30 minutes thereafter to see if GLP-2 increases these parameters compared to placebo.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01958775
|Toronto General Hospital|
|Toronto, Ontario, Canada, M5G 1L7|